TG Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TG Therapeutics, Inc.
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.
Emerging biopharma companies developed and launched 40% of all new drugs that hit the market in the US in 2020, a significant increase from five years ago, according to IQVIA.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Ariston Pharmaceuticals, Inc.
- Atlantic Pharmaceuticals, Inc.
- Atlantic Technology Ventures, Inc.
- Manhattan Pharmaceuticals, Inc.
- Manhattan Research Development, Inc.
- Tarpan Therapeutics, Inc.